Major cardiovascular outcome trials and real-life observations have proven that glucagon-
like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), regardless of structural GLP-1 …

As the worldwide prevalence of diabetes and obesity continues to rise, so does the risk of
debilitating cardiovascular complications. Given the significant association between …

The management of type 2 diabetes continues to evolve as new data emerge. Although
glycaemic control is still important, other risk factors–such as hypertension, dyslipidaemia …

Abstract Glucagon-like peptide 1 (GLP-1) is an incretin hormone responsible for
amplification of insulin secretion when nutrients are given orally, as opposed to …

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that enhances glucose-stimulated
insulin secretion and exerts direct and indirect actions on the cardiovascular system. GLP-1 …

Cardiovascular protective properties of incretin-based thera... : Current Opinion in Lipidology
Cardiovascular protective properties of incretin-based therapies in type 2 diabetes : Current …

Incretins, such as glucagon-like peptide-1 (GLP-1), are gut peptides that stimulate insulin
secretion. Incretin-targeted therapeutics for type 2 diabetes include both direct GLP-1 …

Atherosclerotic cardiovascular disease is a chronic condition that often copresents with type
2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin …

Rates of type 2 diabetes, obesity and their associated detrimental cardiovascular effects are
rapidly increasing. Despite the availability of several treatment options for type 2 diabetes …

Abstract Glucagon-like (GLP-1) is a peptide hormone secreted from the small intestine in
response to nutrient ingestion. GLP-1 stimulates insulin secretion in a glucose-dependent …